The data used to present in this study are controlled by a third party, Taiwan National Health Insurance Research Database. We do not have permission to share the data. Accessing these datasets need to be applied and permitted by the Bureau of National Health Insurance, Department of Health (<http://nhird.nhri.org.tw/en/index.htm>).

Introduction {#sec005}
============

The prevalence of diabetes in the WHO report was estimated to be 422 million peoples throughout the world \[[@pone.0210085.ref001]\]. Uric acid level and hyperuricemia are one of the underlying pathways of gout and a well-studied risk factor for gout \[[@pone.0210085.ref002]\]. Several studies have investigated that the serum uric acid levels and gout are associated with the metabolic syndrome\[[@pone.0210085.ref003]\] and have an independent impact on the risk of cardiovascular disease \[[@pone.0210085.ref004], [@pone.0210085.ref005]\] and developing type 2 diabetes mellitus (T2DM)\[[@pone.0210085.ref006], [@pone.0210085.ref007]\]. Randomized trials have reported that lowering uric acid by using allopurinol improves insulin resistance in asymptomatic hyperuricemic individuals \[[@pone.0210085.ref008], [@pone.0210085.ref009]\], and similar improvement in insulin resistance has been observed with the use of benzbromarone as urate-lowering therapy (ULT)\[[@pone.0210085.ref010]\]. Although ULT might be beneficial in lowering T2DM risk, observational studies have demonstrated that gout may be independently associated with an increased risk of T2DM \[[@pone.0210085.ref011], [@pone.0210085.ref012]\]. The association between ULT and serum uric acid are still controversial in T2DM.

Allopurinol, a xanthine oxidase inhibitor has been approved worldwide to first-line treatment for gout patients with asymptomatic hyperuricemia and comorbid renal or cardiovascular diseases\[[@pone.0210085.ref013]\]. Xanthine oxidase inhibitors block the synthesis of uric acid and can be used regardless of whether urate is overproduced \[[@pone.0210085.ref014]\]. Uricosuric drugs including probenecid, sulfinpyrazone, and benzbromarone, which are second-line therapies for gout, block renal tubular urate reabsorption \[[@pone.0210085.ref014], [@pone.0210085.ref015]\]. Uricosuric drugs predominantly act on urate anion exchanger 1---an organic anion transporter---to prevent the reuptake of uric acid at the proximal renal tubule, thus increasing the renal excretion of uric acid\[[@pone.0210085.ref016], [@pone.0210085.ref017]\]. Benzbromarone (not available in the United States) may be prescribed to patients with mild-to-moderate renal insufficiency but is potentially hepatotoxic, whereas probenecid and sulfinpyrazone are generally ineffective in patients with renal impairment\[[@pone.0210085.ref014]\]. Uricosuric agents are more commonly prescribed than are xanthine oxidase inhibitors\[[@pone.0210085.ref018]\]. Owing to this study, a higher proportion of gout patients in Taiwan are using benzbromarone (approximately 84.8%, n = 25 254) than allopurinol (57.8%, n = 17 199).

To determine whether long-term or excessive ULT protects against **T2DM** risk, we retrospectively analyzed data from a population-based database of Taiwan and evaluated the relationship between ULT and T2DM risk.

Material and methods {#sec006}
====================

Data source and study population {#sec007}
--------------------------------

Data analyzed in this study were retrieved from the Taiwan National Health Insurance Research Database (NHIRD), which was established in 1995 and collects all claims of those insured under the National Health Insurance (NHI) program. The program covers more than 98% of the total population (23,000,000) and has contracted with 97% of the hospitals and clinics in Taiwan\[[@pone.0210085.ref019]\]. For this analysis, we used data from Longitudinal Health Insurance Database 2010 (LHID2010), which is a nationwide database including the claims data of 1 million individuals randomly selected from all insurants in the NHIRD. We conducted a nested case-control study by using data from the NHIRD for the period between January 1998 and December 2010. The diagnoses in the NHIRD are coded according to the International Classification of Diseases, Ninth Revision, Clinical Modification diagnostic (ICD-9-CM). The diagnoses in the claims data of the NHIRD are primarily used for administrative purposes, and anonymity of the data is ensured by assigning identification numbers. The study protocols were reviewed and approved by the China Medical University Ethics Review Committee.

Inclusion and exclusion criteria {#sec008}
--------------------------------

The inclusion criteria were patients newly diagnosed with gout and age ≥20 years, and the study population was followed up for 13 years. The exclusion criteria were age \>100 years and age \<20 years, type 1 diabetes (250.x1 or 250.x3, with x = 0--9), type 2 diabetic patients with clinic visits \<3 and no antidiabetic therapy, gout patients with clinic visits \<3 and inhibiting or increasing uric acid therapy, gout patients with clinic visits \<3 and no inhibiting or increasing uric acid therapy, patients diagnosed with T2DM before December 31, 1998, patients diagnosed with gout before January 1, 1998, and after January 1, 2010, prior diagnosis of T2DM and the first diagnosis date for gout until the index date of T2DM \<1 year. The more detailed information was presented in [Fig 1](#pone.0210085.g001){ref-type="fig"}.

![Schematic of the samples selection process for association between urate-lowering therapy and risk of type 2 diabetes mellitus.](pone.0210085.g001){#pone.0210085.g001}

Ascertainment of gout {#sec009}
---------------------

This study comprises 29 765 gout patients and 59 530 controls (matched at a 1:2 ratio). The primary case definition of gout was having a physician-recorded primary diagnosis (ICD-9-CM 274.x) at an outpatient or inpatient visit. To evaluate the robustness of gout case ascertainment, gout was defined as ≥3 clinic visits with ULT. The agents for ULT inhibited uric acid production (allopurinol, Anatomic Therapeutic Chemical code M04AA01), and those for ULT increased uric acid excretion (probenecid, M04AB01; sulfinpyrazone, M04AB02; and benzbromarone, M04AB03).

We calculated the cumulative exposure dose for ULT, which was derived by dividing the total exposure dose for ULT by the total follow-up days (by the first treatment date for gout among gout patients until the index date of T2DM or to the study end with no events). Simultaneously, we calculated the annual exposure day, which was derived by dividing the total exposure days of ULT by the total follow-up time, and the average exposure dose for ULT, which was derived by dividing the total exposure dose for ULT by the total exposure days. We classified the cumulative exposure dose for allopurinol into the following categories according to the quartile method: none, \>0--1.3, \>1.3--4.2, \>4.2--15.2, and \>15.2, and that for benzbromarone was categorized as follows: none, \>0--1.3, \>1.3--3.4, \>3.4--9.4, and \>9.4. In addition, the quartile method was adopted to classify the annual exposure days for allopurinol (none, \>0--2.5, \>2.5--8.8, \>8.8--37.0, and \>37.0) and benzbromarone (none, \>0--6.6, \>6.6--17.6, \>17.6--49.1, and \>49.1). We classified the average exposure dose for allopurinol in the following categories: none, \>0--100, \>100--200, \>200--300, and \>300, and that for benzbromarone was categorized as follows: none, \>0--50, \>50--100, and \>100.

T2DM outcome assessment {#sec010}
-----------------------

T2DM events were defined as a new occurrence of T2DM events (ICD-9-CM code 250.x0 or 250.x2, with x = 0--9). T2DM was defined as ≥3 clinic visits and antidiabetic treatment. The oral antidiabetic agents were metformin (A10BA), sulfonylureas (A10BB), meglitinides (A10BX), thiazolidinediones (A10BG), and α-glucosidase inhibitor (A10BF). The insulin injection agents were rapid-acting (A10AB), intermediate-acting (A10AC), long-acting (A10AE), and combination (A10AD).

Assessment of covariates {#sec011}
------------------------

From the NHIRD, we collected data on the demographic characteristics of age, sex, and region, as well as the comorbidities of myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, rheumatologic disease, renal disease, and alcohol-related diseases, with diagnoses coded according to ICD-9-CM\[[@pone.0210085.ref020]\].

Statistical analyses {#sec012}
--------------------

Continuous variables are presented as mean (standard deviation) or median (interquartile range), and categorical variables are presented as frequencies (percentages). Continuous and categorical variables were analyzed using a *t*-test or chi-square test for comparisons between gout patients and controls. The dose-response relationship and the annual exposure day for ULT were measured. Moreover, the relationship between diverse exposure doses for ULT and the risk of T2DM was analyzed using the Cox proportional hazards model. Multivariate models were adjusted for the covariates of age group, sex, region, and comorbidities. We also conducted subgroup analyses of gout patients on ULT by sex or age to examine their influence. To assess the robustness of our findings, sensitivity analyses were performed by simultaneously altering the relative risk of the dose-response relationship between ULT doses and the T2DM risk. P values of less than 0.05 were regarded as significant. All statistical analyses were performed using SAS statistical software, version 9.4 (SAS Institute, Cary, NC, USA).

Results {#sec013}
=======

Baseline characteristics of study subjects {#sec014}
------------------------------------------

**We** presented the baseline characteristics of gout patients and controls in the Table **[1](#pone.0210085.t001){ref-type="table"}**. The mean age was 47.3 years among the gout patients. Thus, we adopted age ≤50 years and age \>50 years to classify age-specific subgroups for further analysis in this study. **We** listed only allopurinol and benzbromarone exposure and overall exposure to each agent stratified by T2DM and non- T2DM in [Table 2](#pone.0210085.t002){ref-type="table"}.

10.1371/journal.pone.0210085.t001

###### Characteristics of subjects with gout and controls.

![](pone.0210085.t001){#pone.0210085.t001g}

                                                Gout           Controls       P value
  --------------------------------------------- -------------- -------------- ----------
  Type 2 diabetes, n(%)                         3940 (13.2)    6334 (10.6)    \<0.0001
  Oral anti-diabetic therapy (ATC code), n(%)                                 
      Metformin (A10BA)                         3540 (11.9)    5753 (9.7)     \<0.0001
      Sulfonylureas (A10BB)                     3222 (10.8)    5675 (9.5)     \<0.0001
      Meglitinides (A10BX)                      599 (2.0)      1173 (2.0)     0.6714
      Thiazolidinediones (A10BG)                623 (2.1)      1534 (2.6)     \<0.0001
      α-glucosidase inhibitor (A10BF)           825 (2.8)      1695 (2.8)     0.5202
  Insulin injection therapy (ATC code), n(%)                                  
      Rapid-acting (A10AB),                     484 (1.6)      960 (1.6)      0.8807
      Intermediate-acting (A10AC)               89 (0.3)       276 (0.5)      0.0003
      Combination (A10AD)                       61 (0.2)       205 (0.3)      0.0003
      Long-acting (A10AE)                       60 (0.2)       183 (0.3)      0.0042
  Age mean(SD), years                           55.4 (16.2)    55.3 (16.1)    0.2865
  Gout diagnosis age (SD), years                47.3 (15.9)                   
      Age group, n(%)                                                         
      20 to 30                                  1542 (5.2)     3158 (5.3)     
      \>30 to 40                                4161 (14.0)    8370 (14.1)    
      \>40 to 50                                5794 (19.5)    11466 (19.3)   
      \>50 to 60                                7187 (24.1)    14459 (24.3)   
      \>60 to 70                                4702 (15.8)    9450 (15.9)    
      \>70 to 80                                4001 (13.4)    7934 (13.3)    
      \>80                                      2378 (8.0)     4693 (7.9)     0.9353
  Gender, n(%)                                                                
      Men                                       24561 (82.5)   48995 (82.3)   
      Women                                     5204 (17.5)    10535 (17.7)   0.4303
  Region, n(%)                                                                
      Northern                                  13788 (46.3)   27669 (46.5)   
      Central                                   7177 (24.1)    13936 (23.4)   
      Southern                                  7686 (25.8)    15909 (26.7)   
      Eastern                                   825 (2.8)      1487 (2.5)     
      Offshore islets and other                 289 (1.0)      529 (0.9)      0.9423
  Comorbidities, n(%)                                                         
      Myocardial infarction                     377 (1.3)      451 (0.8)      \<0.0001
      Congestive heart failure                  2256 (7.6)     2121 (3.6)     \<0.0001
      Peripheral vascular disease               1448 (4.9)     1604 (2.7)     \<0.0001
      Cerebrovascular disease                   3580 (12.0)    4982 (8.4)     \<0.0001
      Rheumatologic disease                     1303 (4.4)     982 (1.6)      \<0.0001
      Renal disease                             2162 (7.3)     1285 (2.2)     \<0.0001
      Alcohol-related diseases                  838 (2.8)      598 (1.0)      \<0.0001

SD: standard deviation; Comorbidities were defined as ≥3 outpatient claims.

Continuous and categorical variables were analyzed using a *t* test and chi-square test for comparisons between gout patients and controls.

10.1371/journal.pone.0210085.t002

###### Only allopurinol or benzbromarone use in gout patients.

![](pone.0210085.t002){#pone.0210085.t002g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                    Inhibiting uric acid production\                                       Increasing uric acid excretion\                                             
                                                                                    M04AA01 (Allopurinol)                                                  M04AB03(Benzbromarone)                                                      
  ---------------------------------------------------------- ---------------------- ---------------------------------- ---------------------- ------------ --------------------------------- -------------------- -------------------- ------------
  Males, n                                                   3182                   375                                2807                                9787                              975                  8812                 

      Follow-up duration, median(IQR), years                 6.5 (3.6--9.2)         4.5 (2.5--6.8)                     6.7 (3.8--9.4)         \<0.0001     6.7 (3.6--9.4)                    4.4 (2.5--6.8)       7 (3.9--9.5)         \<0.0001

      Total clinic visits, median(IQR), frequencies          3 (2--8)               4 (2--11)                          3 (1--8)               0.0028       4 (2--10)                         5 (2--13)            4 (2--10)            0.0002

      Total drug use, median (IQR), days                     43 (14--147)           56 (14--180)                       42 (14--141)           0.0316       90 (30--224)                      97 (30--280)         88.5 (30--219)       0.0683

      Total drug tablets, median (IQR), quantities           70 (28--212)           90 (30--294)                       65 (28--203)           0.0040       97 (42--252)                      115 (42--341)        93 (42--240.5)       0.0070

      Total dosage, median (IQR), mg                         7650 (2800--22700)     9100 (3000--29900)                 7000 (2800--22400)     0.0096       6000 (2800--15600)                7000 (2800--20050)   6000 (2800--15100)   0.0178

      Total dosage(mg) /Follow-up duration(years×365 days)   4.2 (1.3--15.1)        7.6 (2.3--24.7)                    3.8 (1.3--14)          \<0.0001     3.3 (1.2--9.1)                    5.2 (1.8--14.7)      3.1 (1.2--8.6)       \<0.0001

      Total drug use(day)/Follow-up duration(years)          8.6 (2.6--36.3)        14.4 (4.6--56.1)                   8.1 (2.3--33.8)        \<0.0001     17.2 (6.5--48)                    26.8 (8.9--76.7)     16.5 (6.3--45.3)     \<0.0001

  **    Total dosage(mg)/Total drug use(day)**               **200 (100--300)**     **200 (100--300)**                 **200 (100--300)**     **0.3930**   **63.7 (50--100)**                **67.6 (50--100)**   **63.5 (50--100)**   **0.0291**

  Females, n                                                 911                    176                                735                                 2536                              507                  2029                 

      Follow-up duration, median(IQR), years                 6.5 (3.4--9.2)         3.9 (2.2--6.4)                     7.1 (4.1--9.6)         \<0.0001     6.5 (3.5--9.1)                    4.1 (2.2--6.3)       7.1 (4--9.5)         \< .0001

      Total clinic visits, median(IQR), frequencies          4 (2--9)               4 (2--14.5)                        4 (1--8)               0.0651       4 (2--10)                         5 (2--12)            4 (2--9)             0.0648

      Total drug use, median (IQR), days                     53 (14--168)           52.5 (16.5--233)                   53 (14--152)           0.1744       90 (36--235)                      91 (35--266)         90 (37--229)         0.6038

      Total drug tablets, median (IQR), quantities           79 (28--240)           84 (28--383.5)                     78 (24--212)           0.0574       107 (44--261)                     116 (42--300)        105 (44--250)        0.2896

      Total dosage, median (IQR), mg                         8400 (2800--25200)     8700 (2800--38350)                 8400 (2700--22400)     0.0762       6250 (2900--16300)                6750 (3000--17200)   6000 (2900--15600)   0.5745

      Total dosage(mg) /Follow-up duration(years×365 days)   4.3 (1.2--16.1)        7.5 (1.8--31.8)                    3.8 (1.1--13.7)        \<0.0001     3.8 (1.3--10.1)                   5.6 (2.2--15.1)      3.4 (1.2--9.3)       \<0.0001

      Total drug use(day)/Follow-up duration(years)          9.3 (2.3--39.3)        13.6 (3.8--87)                     8.5 (2.1--34.4)        0.0001       19.7 (7.1--55.1)                  29 (11.1--82.2)      17.3 (6.4--47.8)     \<0.0001

  **    Total dosage(mg)/Total drug use(day)**               **183.3 (100--300)**   **200 (100--277.2)**               **180 (100--300)**     **0.9179**   **56.3 (50--100)**                **54.9 (50--100)**   **56.3 (50--100)**   **0.9299**

  Combined group, n                                          4093                   551                                3542                                12323                             1482                 10841                

      Follow-up duration, median(IQR), years                 6.5 (3.5--9.2)         4.3 (2.5--6.7)                     6.8 (3.8--9.4)         \<0.0001     6.7 (3.6--9.3)                    4.2 (2.4--6.6)       7 (3.9--9.5)         \<0.0001

      Total clinic visits, median(IQR), frequencies          3 (2--8)               4 (2--13)                          3 (1--8)               0.0004       4 (2--10)                         5 (2--12)            4 (2--9)             \<0.0001

      otal drug use, median (IQR), days                      45 (14--150)           56 (15--201)                       42 (14--144)           0.0116       90 (32--224)                      95 (31--271)         90 (33--222)         0.0314

      Total drug tablets, median (IQR), quantities           70 (28--221)           90 (28--329)                       69 (28--207)           0.0007       98 (42--254)                      116 (42--325)        96 (42--242)         0.0022

      Total dosage, median (IQR), mg                         7900 (2800--23800)     9000 (3000--33000)                 7400 (2800--22400)     0.0021       6000 (2800--15700)                7000 (2800--19000)   6000 (2800--15300)   0.0118

      Total dosage(mg) /Follow-up duration(years×365 days)   4.2 (1.3--15.2)        7.6 (2.1--26.8)                    3.8 (1.2--13.9)        \<0.0001     3.4 (1.3--9.4)                    5.4 (1.9--14.9)      3.2 (1.2--8.7)       \<0.0001

      Total drug use(day)/Follow-up duration(years)          8.8 (2.5--37)          13.8 (4.2--59.2)                   8.2 (2.3--33.8)        \<0.0001     17.6 (6.6--49.1)                  27.7 (9.7--77.7)     16.6 (6.3--45.9)     \<0.0001

  **    Total dosage(mg)/Total drug use(day)**               **200 (100--300)**     **200(100--300)**                  **197.9 (100--300)**   **0.5660**   **62.5 (50--100)**                **63 (50--100)**     **62.5 (50--100)**   **0.1631**
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IQR: interquartile range.

Continuous variables were analyzed using a *t* test for comparisons between type 2 diabetes and non-type 2 diabetes among gout patients.

The relative risk for of T2DM with allopurinol or benzbromarone use {#sec015}
-------------------------------------------------------------------

As shown in [Table 3](#pone.0210085.t003){ref-type="table"} and [S1 Table](#pone.0210085.s001){ref-type="supplementary-material"}, the hazard ratio (HR) for the relationship of T2DM with allopurinol or benzbromarone use was 1.17 (95% CI 1.07--1.28) or 1.09 (95% CI 1.03--1.15), respectively. We found that **T2DM** risk was higher in allopurinol or benzbromarone users than in nonuser controls. Compared with nonuser controls, the HR for the cumulative allopurinol dose was 0.87 (95% CI 0.71--1.07) for patients on ≤1.3 mg/day and were 1.31 (95% CI 1.13--1.52) for those on \>15.2 mg/day. Similarly, the HR for the cumulative benzbromarone dose was 0.85 (95% CI 0.75--0.96) for patients on ≤1.3 mg/day and 1.42(95% CI 1.30--1.55) for those on \>9.4 mg/day. In sensitivity analysis 1, we similarly showed the dose--response relationship between ULT doses and the T2DM risk. In sensitivity analysis 2, the HR for T2DM increased from 0.92 to 1.45 with allopurinol exposure doses and from 1.06 to 1.47 with benzbromarone exposure doses.

10.1371/journal.pone.0210085.t003

###### Association between allopurinol or benzbromarone use and risk of developing type 2 diabetes.

![](pone.0210085.t003){#pone.0210085.t003g}

  ---------------------------------------------------------------------------------------------------------------------------------------------
                                                                      Type 2 diabetes\   Total people, n   Adjusted HR\            P value
                                                                      events, n (%)                        (95% CI)                
  ------------------------------------------------------------------- ------------------ ----------------- ----------------------- ------------
  Allopurinol (M04AA01)                                                                                                            

      Cumulative exposure dose[\*](#t003fn004){ref-type="table-fn"}                                                                

        Non use                                                       6334 (10.64)       59530             1.00                    

        Use, mg/day                                                                                                                

          \>0 to 1.3                                                  89 (8.73)          1019              0.87 (0.71--1.07)       0.1908

          \>1.3 to 4.2                                                119 (11.58)        1028              1.12 (0.93--1.34)       0.2293

          \>4.2 to 15.2                                               156 (15.26)        1022              1.30 (1.11--1.53)       0.0012

          \>15.2                                                      187 (18.26)        1024              1.31 (1.13--1.52)       0.0003

  **        Increasing uric acid excretion**                          **1501 (11.94)**   **12566**         **1.09 (1.03--1.15)**   **0.0036**

          Combination therapy                                         1647 (12.57)       13106             1.03 (0.98--1.09)       0.2693

  Benzbromarone (M04AB03)                                                                                                          

      Cumulative exposure dose                                                                                                     

        Non use                                                       6334 (10.64)       59530             1.00                    

        Use, mg/day                                                                                                                

          \>0 to 1.3                                                  270 (8.51)         3174              0.85 (0.75--0.96)       0.0092

          \>1.3 to 3.4                                                297 (9.84)         3018              0.96 (0.85--1.08)       0.4706

          \>3.4 to 9.4                                                374 (12.26)        3050              1.08 (0.97--1.20)       0.1404

          \>9.4                                                       541 (17.56)        3081              1.42 (1.30--1.55)       \<0.0001

  **        Allopurinol**                                             **551 (13.46)**    **4093**          **1.17 (1.07--1.28)**   **0.0004**

          Probenecid or Sulfinpyrazone                                19 (7.82)          243               0.76 (0.48--1.19)       0.2231

          Combination therapy                                         1647 (12.57)       13106             1.03 (0.98--1.09)       0.2594

  Sensitivity analysis 1**[†](#t003fn005){ref-type="table-fn"}**                                                                   

      Allopurinol (M04AA01)                                                                                                        

        Cumulative exposure dose                                                                                                   

        Non use                                                       6334 (10.64)       59530             1.00                    

        Use, mg/day                                                                                                                

          \>0 to 1.3                                                  379 (9.35)         4055              0.89 (0.80--0.99)       0.0309

          \>1.3 to 4.2                                                464 (10.81)        4292              0.99 (0.90--1.09)       0.8522

          \>4.2 to 15.2                                               627 (14.05)        4464              1.16 (1.07--1.26)       0.0003

          \>15.2                                                      728 (16.59)        4388              1.16 (1.07--1.25)       0.0003

          Other                                                       1501 (11.94)       12566             1.09 (1.03--1.15)       0.0034

  Benzbromarone (M04AB03)                                                                                                          

      Cumulative exposure dose                                                                                                     

        Non use                                                       6334 (10.64)       59530             1.00                    

        Use, mg/day                                                                                                                

          \>0 to 1.3                                                  542 (9.04)         5997              0.86 (0.79--0.94)       0.0006

          \>1.3 to 3.4                                                615 (10.3)         5969              0.95 (0.87--1.03)       0.2200

          \>3.4 to 9.4                                                828 (12.63)        6558              1.08 (1.00--1.16)       0.0491

          \>9.4                                                       1128 (16.76)       6730              1.29 (1.21--1.38)       \<0.0001

          Other                                                       586 (12.99)        4511              1.14 (1.05--1.24)       0.0029

  Sensitivity analysis 2[‡](#t003fn006){ref-type="table-fn"}                                                                       

      Allopurinol (M04AA01)                                                                                                        

        Average exposure dose                                                                                                      

          Non use                                                     6334 (10.64)       59530             1.00                    

          Use, mg/day                                                                                                              

          \>0 to 100                                                  151 (11.70)        1291              0.92 (0.78--1.08)       0.2927

          \>100 to 200                                                193 (15.45)        1249              1.28 (1.11--1.48)       0.0007

          \>200 to 300                                                184 (13.28)        1386              1.31 (1.13--1.52)       0.0003

          \>300                                                       23 (13.77)         167               1.45 (0.96--2.19)       0.0742

  **        Increasing uric acid excretion**                          **1501 (11.94)**   **12566**         **1.09 (1.03--1.15)**   **0.0038**

          Combination therapy                                         1647 (12.57)       13106             1.03 (0.97--1.09)       0.2958

      Benzbromarone (M04AB03)                                                                                                      

        Average exposure dose                                                                                                      

          Non use                                                     6334 (10.64)       59530             1.00                    

          Use, mg/day                                                                                                              

            \>0 to 50                                                 601 (11.67)        5148              1.06 (0.97--1.15)       0.1945

            \>50 to 100                                               760 (11.92)        6377              1.08 (1.00--1.16)       0.0475

            \>100                                                     121 (15.16)        798               1.47 (1.23--1.76)       \<0.0001

  **Allopurinol**                                                     **551 (13.46)**    **4093**          **1.17 (1.07--1.28)**   **0.0005**

  Probenecid or Sulfinpyrazone                                        19 (7.82)          243               0.76 (0.48--1.18)       0.2218

  Combination therapy                                                 1647 (12.57)       13106             1.03 (0.98--1.09)       0.2823
  ---------------------------------------------------------------------------------------------------------------------------------------------

Drugs used for increasing uric acid excretion were probenecid (M04AB01), sulfinpyrazone (M04AB02), and benzbromarone (M04AB03)

Combination therapy involved allopurinol and drugs used for increasing uric acid excretion

Adjusted HR was calculated and adjusted for age group, sex, region, and comorbidities by using a Cox proportional hazards regression model.

\*Cumulative exposure allopurinol or benzbromarone dose: the accumulated allopurinol or benzbromarone dose divided by the total follow-up days (by the first treat gout date until the index date of type 2 diabetes or to the study end).

**†**Sensitivity analysis 1 was calculated as all allopurinol or benzbromarone use in gout patients (versus controls).

‡Sensitivity analysis 2 was calculated as total dose/total drug use day in gout patients (versus controls).

Developing risk of T2DM stratified by sex {#sec016}
-----------------------------------------

[Table 4](#pone.0210085.t004){ref-type="table"} shows the association between allopurinol or benzbromarone use and the **T2DM** risk stratified by sex. The HR for the association of **T2DM** in women, were 1.19 (95% CI 1.02--1.40) for allopurinol use and 1.25 (95% CI 1.13--1.38) for benzbromarone use, respectively. However, only men with allopurinol use had a higher T2DM risk (HR = 1.16, 95% CI 1.05--1.29), and no significantly higher T2DM risk was found among men with benzbromarone use (HR = 1.02, 95% CI 0.95--1.10). Similarly, the higher T2DM risk was observed in patients taking high doses of allopurinol or benzbromarone compared those with nonuser among men and women.

10.1371/journal.pone.0210085.t004

###### Association between allopurinol or benzbromarone use and risk of developing type 2 diabetes stratified by sex.

![](pone.0210085.t004){#pone.0210085.t004g}

                                                          Men                                                   Women                       
  ---------------------------------------- -------------- ------- ------------------- ---------- -------------- ------- ------------------- ----------
  Allopurinol (M04AA01)                                                                                                                     
      Cumulative exposure dose                                                                                                              
        Non use                            4693 (9.58)    48995   1.00                           1641 (15.58)   10535   1.00                
        Use, mg/day                                                                                                                         
          \>0 to 1.3                       56 (7.24)      774     0.82 (0.63--1.07)   0.1506     33 (13.47)     245     0.96 (0.68--1.35)   0.7982
          \>1.3 to 4.2                     83 (10.11)     821     1.11 (0.89--1.38)   0.3577     36 (17.39)     207     1.14 (0.82--1.59)   0.4226
          \>4.2 to 15.2                    113 (14.2)     796     1.38 (1.15--1.67)   0.0006     43 (19.03)     226     1.14 (0.84--1.54)   0.3983
          \>15.2                           123 (15.55)    791     1.25 (1.04--1.50)   0.0150     64 (27.47)     233     1.46 (1.14--1.88)   0.0030
          Increasing uric acid excretion   985 (9.88)     9972    1.02 (0.95--1.10)   0.5178     516 (19.89)    2594    1.25 (1.13--1.38)   \<0.0001
          Combination therapy              1293 (11.34)   11407   1.00 (0.94--1.07)   0.9170     354 (20.84)    1699    1.13 (1.01--1.28)   0.0365
  Benzbromarone (M04AB03)                                                                                                                   
      Cumulative exposure dose                                                                                                              
        Non use                            4693 (9.58)    48995   1.00                           1641 (15.58)   10535   1.00                
        Use, mg/day                                                                                                                         
          \>0 to 1.3                       189 (7.43)     2544    0.84 (0.73--0.97)   0.0207     81 (12.86)     630     0.87 (0.69--1.08)   0.2128
          \>1.3 to 3.4                     198 (8.08)     2450    0.89 (0.77--1.03)   0.1076     99 (17.43)     568     1.13 (0.92--1.39)   0.2315
          \>3.4 to 9.4                     227 (9.49)     2393    0.96 (0.84--1.10)   0.5814     147 (22.37)    657     1.35 (1.14--1.60)   0.0005
          \>9.4                            361 (15.04)    2400    1.37 (1.23--1.52)   \<0.0001   180 (26.43)    681     1.55 (1.33--1.82)   \<0.0001
          Allopurinol                      375 (11.79)    3182    1.16 (1.05--1.29)   0.0055     176 (19.32)    911     1.19 (1.02--1.40)   0.0267
          Probenecid or Sulfinpyrazone     10 (5.41)      185     0.63 (0.34--1.17)   0.1401     9 (15.52)      58      1.00 (0.52--1.92)   0.9903
          Combination therapy              1293 (11.34)   11407   1.00 (0.94--1.07)   0.8957     354 (20.84)    1699    1.14 (1.01--1.28)   0.0356

Drugs used for increasing uric acid excretion were probenecid (M04AB01), sulfinpyrazone (M04AB02), and benzbromarone (M04AB03)

Combination therapy involved allopurinol and drugs used for increasing uric acid excretion

Adjusted HR was calculated and adjusted for age group, region, and comorbidities by using a Cox proportional hazards regression model.

Cumulative exposure allopurinol or benzbromarone dose: the accumulated allopurinol or benzbromarone dose divided by the total follow-up days (by the first treat gout date until the index date of type 2 diabetes or to the study end).

Developing risk of T2DM stratified by age {#sec017}
-----------------------------------------

**[Table 5](#pone.0210085.t005){ref-type="table"}** shows the association between the allopurinol or benzbromarone use and the type 2 diabetes risk stratified by age ≤50 years and age \>50 years. The HR for the association of T2DM with allopurinol or benzbromarone use was 2.28 (95% CI 1.84--2.81) or 1.90 (95% CI 1.64--2.20) in patients aged ≤50 years, respectively. A consistent result was found in those taking high doses. Patients with allopurinol or benzbromarone use by annual exposure day had higher risk for developing T2DM ([S2 Table](#pone.0210085.s002){ref-type="supplementary-material"}), whereas the HR for patients in aged \>50 years group with cumulative dose ≤1.3 mg/day of allopurinol or benzbromarone had lower risk of T2DM (HR = 0.74, 95% CI 0.58--0.94 for allopurinol; HR = 0.79, 95% CI 0.69--0.90 for benzbromarone).

10.1371/journal.pone.0210085.t005

###### Association between allopurinol or benzbromarone use and risk of developing type 2 diabetes stratified by age group.

![](pone.0210085.t005){#pone.0210085.t005g}

                                                                                              Age≤50 years                                                 Age\>50 years                       
  ------------------------------------------------------------------------------ ------------ -------------- ------------------- ---------- -------------- --------------- ------------------- ----------
  Allopurinol (M04AA01)                                                                                                                                                                        
      Cumulative exposure dose                                                                                                                                                                 
        Non use                                                                  593 (2.58)   22994          1.00                           5741(15.71)    36536           1.00                
        Use, mg/day                                                                                                                                                                            
          \>0 to 1.3                                                             22 (4.88)    451            1.82 (1.19--2.79)   0.0058     67 (11.80)     568             0.74 (0.58--0.94)   0.0126
          \>1.3 to 4.2                                                           27 (6.08)    444            2.31 (1.57--3.40)   \<0.0001   92 (15.75)     584             0.98 (0.80--1.20)   0.8460
          \>4.2 to 15.2                                                          25 (6.25)    400            2.17 (1.45--3.25)   0.0002     131 (21.06)    622             1.20 (1.01--1.43)   0.0375
          \>15.2                                                                 28 (9.24)    303            2.93 (2.00--4.30)   \<0.0001   159 (22.05)    721             1.17 (1.00--1.37)   0.0494
          Increasing uric acid excretion[^¶^](#t005fn001){ref-type="table-fn"}   267 (5.19)   5146           1.90 (1.64--2.20)   \<0.0001   1234 (16.63)   7420            0.99 (0.93--1.05)   0.7127
          Both use[\*](#t005fn002){ref-type="table-fn"}                          326 (6.86)   4753           2.31 (2.01--2.65)   \<0.0001   1321 (15.81)   8353            0.89 (0.84--0.95)   0.0002
  Benzbromarone (M04AB03)                                                                                                                                                                      
      Cumulative exposure dose                                                                                                                                                                 
        Non use                                                                  593 (2.58)   22994          1.00                           5741 (15.71)   36536           1.00                
        Use, mg/day                                                                                                                                                                            
          \>0 to 1.3                                                             56 (3.72)    1506           1.45 (1.10--1.90)   0.0083     214 (12.83)    1668            0.79 (0.69--0.90)   0.0006
          \>1.3 to 3.4                                                           61 (4.59)    1328           1.77 (1.36--2.31)   \<0.0001   236 (13.96)    1690            0.86 (0.75--0.97)   0.0191
          \>3.4 to 9.4                                                           71 (5.96)    1191           2.13 (1.66--2.72)   \<0.0001   303 (16.30)    1859            0.96 (0.85--1.07)   0.4415
          \>9.4                                                                  74 (7.38)    1003           2.40 (1.88--3.06)   \<0.0001   467 (22.47)    2078            1.29 (1.17--1.42)   \<0.0001
          Allopurinol                                                            102 (6.38)   1598           2.28 (1.84--2.81)   \<0.0001   449 (18.00)    2495            1.05 (0.95--1.15)   0.3684
          Probenecid or Sulfinpyrazone                                           5 (4.24)     118            1.56 (0.65--3.77)   0.3194     14 (11.20)     125             0.66 (0.39--1.12)   0.1257
          Both use[\*](#t005fn002){ref-type="table-fn"}                          326 (6.86)   4753           2.31 (2.01--2.65)   \<0.0001   1321(15.81)    8353            0.89 (0.84--0.95)   0.0003

^¶^Drugs used for increasing uric acid excretion were probenecid (M04AB01), sulfinpyrazone (M04AB02), and benzbromarone (M04AB03)

\*Combination therapy involved allopurinol and drugs used for increasing uric acid excretion

Adjusted HR was calculated and adjusted for age group, sex, region, and comorbidities by using a Cox proportional hazards regression model.

Cumulative exposure allopurinol or benzbromarone dose: the accumulated allopurinol or benzbromarone dose divided by the total follow-up days (by the first treat gout date until the index date of type 2 diabetes or to the study end).

Discussion {#sec018}
==========

The results of this nested case-control study indicated that allopurinol or benzbromarone use is associated with the risk of developing T2DM, particularly in patients receiving high doses of allopurinol or benzbromarone and those with prolonged use. Such consistent result was also found in sex-specific and age-specific subgroup analysis. Compared with gout patients older than 50 years, we found that gout patients younger than 50 years were at a higher risk of T2DM. Uric acid-lowering therapy in gout patients may not be beneficial in lowering T2DM risk, particularly in gout patients younger than 50 years. Although gout patients with age greater than 50 years and a low dose of ULT may be beneficial in lowering T2DM risk, further clinical studies need to be confirmed these associations.

Gout and hyperuricemia have been linked with an increased occurrence of several comorbidities, such as coronary artery disease and hypertension \[[@pone.0210085.ref021]\], chronic kidney disease \[[@pone.0210085.ref022]\] or T2DM \[[@pone.0210085.ref023]\]. However, it is unknown whether the high serum uric acid is a causal factor in the development of these conditions or is a consequence of the manifestation of these disorders. In this study, gout patients older than 50 years with two ULT treatments had a protective effect on T2DM risk (HR = 0.89, 95% CI 0.84--0.95, P = 0.0002). The protective effect was also observed in the low dose of allopurinol or benzbromarone treatment in the older patients group (age \>50 years old). The effects of ULT on developing T2DM risk were controversial in the different age groups. Because individuals with gout generally have an increased prevalence of hypertension, a decline in renal function\[[@pone.0210085.ref024]\] and obesity\[[@pone.0210085.ref025]\], these co-morbidities are well-known risk factors of T2DM and may modify the effects of ULT on developing T2DM risk. Further large studies need to be conducted to examine the interaction between co-morbidities and reduction of serum uric acid levels in developing T2DM risk.

We found a significant effect of ULT modification by sex, with the higher magnitude of the association among women than men. The mechanisms underlying the association of UA with the development of T2DM are not completely understood. Several potential pathophysiological mechanisms have been proposed, including inflammation, sex hormones, medication modification, and genetic effects. Ongoing low-grade inflammation in gout patients may promote the diabetogenic process. The differences in the baseline serum level between men and women and the difference in uric acid metabolism may explain the higher risk of diabetes in female gout patients compared with in male gout patients\[[@pone.0210085.ref012]\]. Sex hormones play a role in this regard. It is proposed that increased renal clearance of urate related to estrogen in premenopausal women may account for the lower SUA levels observed in women than in men \[[@pone.0210085.ref026]\]. A conceivable mechanism underlying the association between hyperuricemia and the risk of T2DM may occur at the renal level\[[@pone.0210085.ref011]\]. For example, urate transporter genes *ABCG2*, *SLC2A9*, and *SLC22A12* modulate the relationship of renal urate homeostasis and gout\[[@pone.0210085.ref027]\] with T2DM. Although Mendelian randomization studies have shown that uric acid-associated loci are causally associated with gout incidence \[[@pone.0210085.ref028]\], no evidence of a causal association between uric acid-associated loci and T2DM is available for European and South Asian populations\[[@pone.0210085.ref023], [@pone.0210085.ref028], [@pone.0210085.ref029]\]. In addition, we found that only benzbromarone use and combination therapy were associated with a higher T2DM risk in women compared to men ([Table 4](#pone.0210085.t004){ref-type="table"}).These findings support the evidence that impact of gout on T2DM risk was higher among women. \[[@pone.0210085.ref012]\]. However, no such difference was found for allopurinol use. Uricosuric drugs may enhance the renal excretion of oxypurinol, the active metabolite of allopurinol, thus reducing the efficacy of allopurinol\[[@pone.0210085.ref030], [@pone.0210085.ref031]\].

According to a 15-year follow-up study, hyperuricemia often precedes the development of hyperinsulinemia, impaired fasting glucose, and diabetes, particularly in young adults \[[@pone.0210085.ref032]\]. The American College of Rheumatology guidelines recommends that plasma urate should be maintained at a concentration less than 360 μmol/L (6 mg/dL) for all patients on ULT\[[@pone.0210085.ref033]\]. ULT is indicated for patients with recurrent gout attacks, chronic arthropathy, tophi, and gout with uric acid stones\[[@pone.0210085.ref015]\]. Although effective treatments exist that eliminate sodium urate crystals and "cure" the disease, the management of gout is often suboptimal\[[@pone.0210085.ref016]\]. Allopurinol and benzbromarone improve insulin resistance\[[@pone.0210085.ref008]--[@pone.0210085.ref010]\], and they may be beneficial in lowering the risk of type 2 diabetes. However, most doctors focus solely on managing acute attacks rather than long-term therapy, and only one-third to one-half of gout patients ever receive ULT\[[@pone.0210085.ref016], [@pone.0210085.ref034]\]; furthermore, adherence to ULT is often poor (10%--46%)\[[@pone.0210085.ref035], [@pone.0210085.ref036]\]. Studies have shown that only 30%--60% of patients are prescribed allopurinol 1 year after the initiation of therapy, and that the management of gout is frequently inappropriate\[[@pone.0210085.ref015], [@pone.0210085.ref037]\]. Studies have demonstrated that treatment provided to reach the serum urate target with dose escalation of ULT is effective for achieving the therapeutic target in most (82%--92%) gout patients \[[@pone.0210085.ref038]--[@pone.0210085.ref040]\]. The management of gout is poor in Taiwan, with only one in five affected people being treated with ULT\[[@pone.0210085.ref018]\], suggesting that uric acid-lowering therapies in gout patients may not be beneficial in lowering T2DM risk in Taiwan.

This study has some strengths and limitations. This study was performed using data from a large population-based database in Taiwan. Therefore, the findings are likely applicable to the general population. Because the definition of gout and T2DM is based on ICD-9-CM diagnoses, a certain level of misclassification of exposure is inevitable. The identification of gout patients was based on ICD codes without the examination of synovial fluid or tophus aspirate for monosodium urate crystals, which may have led to some misclassification bias. We used a strict definition of gout requiring three clinic visits with ULT, which was found to have a high positive predictive value for fulfilling the various classification criteria for gout in primary care \[[@pone.0210085.ref041]\]. Several important covariates that are also associated with the risk of type 2 diabetes and gout(eg blood pressure, body mass index, use of diuretics, diet, consumption of alcohol, glucose levels, cholesterol, triglycerides, creatinine), could not be taken into account because of a lack of data. There is, thus, a possible risk for underestimation of some comorbidities, in particular hypertension, hyperlipidemia, obesity renal disease, and alcohol-related diseases, when ICD codes are used for definitions. In addition, we could not ascertain whether the patients had continued exposure to ULT beyond the index prescription date; thus, an immortal time bias may occur\[[@pone.0210085.ref042]\]. Nevertheless, we excluded immortal time by defining the start of follow-up for the treated group as the start of treatment for all subjects who received the urate-lowering drugs under investigation. Thus, patients were enrolled in the cohort at the time of their first prescription. Because of the lack of uric acid level at baseline, a detection bias may have occurred because persons with gout having higher uric acid values may more often visit doctors compared with those who are well-controlled. This could increase the likelihood of being diagnosed with T2DM. Individuals with T2DM have lower numbers of missing values for possible confounders such as hypertension, hyperlipidemia, obesity and renal disease. This may have led to residual confounding. Finally, although all included studies adjusted for a wide range of potential confounders for risk of developing T2DM, we cannot definitively exclude possible residual confounding effects because serum biochemistry, lifestyle, nutrition, and physical activity, are not routinely recorded in the NHIRD.

In conclusion, this study used data from a population-based database to determine a substantial association between ULT and a higher T2DM risk, particularly in gout patients younger than 50 years and those with prolonged ULT and a high dose of ULT. Despite the availability of effective ULT, only 22.93% of gout patients are prescribed urate-lowering treatment in Taiwan, which remained unchanged between 2005 and 2010\[[@pone.0210085.ref018]\], possibly contributing to elevated urate doses and increased gout flares with major adverse consequences such as T2DM. These findings support appropriate recognition and management of the risk factor of T2DM by using ULT for hyperuricemia in gout patients.
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